COVID-19 Resources and Services from WCG:
COVID-19 Webinar Series
Join the next COVID-19 Webinar
Join thousands of your peers in WCG’s online panels, where clinical trial and public health experts provide the latest insights on COVID-19 and discuss the biggest questions and topics you submit.
COVID-19 Clinical Trial Tracker
Monitor the progress of clinical trials for COVID-19 treatments and vaccines, leveraging data from the WCG Knowledge Base™.
COVID-19 Trial Insights from the WCG Knowledge Base™
About WCG Trial Insights
The WCG Trial Insights series brings you weekly insights on trial activity throughout the COVID-19 crisis, based on the extensive services we provide to life science clients and supported by our proprietary and powerful WCG Knowledge Base™.
WCG COVID-19 Advisory Services
Need help interpreting critical data to navigate the impact of COVID-19 on trials and sites? We leverage insights and benchmark data from the WCG Knowledge Base to guide best practices for trial performance during this unprecedented time.
Insights from April 23, 2021
Recent Insights from WCG
The map below displays WCG locations. The same locations are listed below the map.
Watch Recent COVID-19 Webinars
Recent news on COVID-19 and clinical trials
News provided by WCG FDAnews and WCG CenterWatch
EMA Streamlines Assessments of COVID-19 and Non-COVID-19 Products
The European Medicines Agency (EMA) is introducing new measures to streamline assessments and approvals of COVID-19 vaccines and treatments.
bioMérieux Earns CE Mark for COVID-19 Antibody Serology Test
The assay can be run by hospital and laboratory staff on the company’s Mini Vidas, Vidas and Vidas 3 immunoassay analyzers.
EMA Safety Committee Investigates Pfizer Vaccine-Associated Facial Swelling
The committee is also monitoring the Pfizer/BioNTech and Moderna vaccines for reports of blood clots.
AstraZeneca May Skip EUA Process and Seek Full Vaccine Approval
AstraZeneca (AZ) may forgo seeking Emergency Use Authorization (EUA) from the FDA and instead go for full approval for its COVID-19 vaccine off the bat.
FDA Authorizes Pfizer/BioNTech Coronavirus Vaccine for Use in Adolescents
The FDA has expanded the Emergency Use Authorization (EUA) for Pfizer and BioNTech’s mRNA-based vaccine, allowing the inoculation to be used in patients 12 to 15 years old.
Inovio’s COVID-19 Vaccine Poised for Phase 3 Trial, but FDA Partial Hold Remains
Inovio said the results from the 400-person phase 2 study will help answer the agency’s questions and that the phase 3 trial will advance once the hold is lifted.
Pfizer/BioNTech File for Full COVID-19 Vaccine Approval
First to receive Emergency Use Authorization (EUA) for their highly effective COVID-19 vaccine, Pfizer and BioNTech have now become first to submit a biologics license application (BLA) with the FDA for full approval of their inoculation.
Moderna CEO Not Upset About President Biden’s Willingness to Waive IP Rights for Vaccines
Bancel reasoned that such a waiver wouldn’t “change anything for Moderna.”
Despite U.S. Backing, Doubt Persists on Possible Patent Waiver Agreement at WTO
President Biden made headlines this week by voicing strong support for waiving COVID-19 vaccine intellectual property (IP) rights during the pandemic, but any deal hashed out at the World Trade Organization (WTO) could come too late to make a significant impact.
Moderna's Booster Shot Increases Antibody Levels Against COVID-19 Variants
Preliminary results will be submitted for peer review upon completion of the strain-matched booster arm of the trial, the company said.
Biden Supports WTO Proposal to Waive COVID-19 Vaccine Patents
President Biden will support a World Trade Organization (WTO) proposal to waive patent protections for COVID-19 vaccines during the pandemic, marking a seismic shift in U.S. policy on intellectual property protections.
FDA Outlines Priority Plan for Inspections
The FDA said yesterday that it plans to gradually resume its on-site drugmaker inspections beginning in July with the intent to be back to normal operations by September.
Expert insights on clinical trials and COVID-19
As we navigate COVID-19 together, our clinical trial experts are engaged to address the biggest questions. To submit a topic or question, use the form at the bottom of the page.
Submit a COVID-19 question or topic to be considered in future webinars
Please note: protocol-specific questions for studies under the oversight of a WCG IRB should be submitted through your IRB contact person, not through this form.
Disclaimer: All information available on this site is intended for your general knowledge and is not for the purpose of providing regulatory advice, medical advice, or a substitute for institutional review board review. You should not use this information to determine compliance with any applicable laws or regulations governing institutional review boards and human subjects research.